A Study to Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Volunteers - Trial NCT06010680
Access comprehensive clinical trial information for NCT06010680 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Recruiting. The study focuses on Lymphoma. Target enrollment is 8 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Jiangsu HengRui Medicine Co., Ltd.
Timeline & Enrollment
Phase 1
Oct 07, 2023
Dec 03, 2023
Primary Outcome
Cumulative recovery and recovery rate of total radioactive substance in urine and feces,Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC),Percentage of parent drug and its metabolites in urine and feces as a percentage of administered dose (%Dose),Radioactivity Tmax,Radioactivity Cmax,Radioactivity AUC,Radioactivity t1/2,Radioactivity CL/F,Radioactivity Vz/F,1Total radioactivity ratio for blood/plasma
Summary
Evaluate the Mass Balance of [14C]SHR2554 in Healthy Adult Male Volunteers.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06010680
Non-Device Trial